Immunovaccine Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com Company invites individual and institutional investors to view October 4th presentation
NEW YORK, Oct. 8, 2012 /PRNewswire/ -- Immunovaccine Inc., (TSX-V: IMV), a clinical stage vaccine company, announced that their October 4th RetailInvestorConferences.com presentation is now available for on-demand viewing.
LINK: www.retailinvestorconferences.com > red "register/ watch event now" button
Immunovaccine's presentation will be available for 90 days. Investors may download shareholder materials from the "virtual trade booth" for the next three weeks.
About Immunovaccine Inc.
Immunovaccine Inc. (TSX-V: IMV) applies its novel adjuvanting platform to the development of vaccines for cancer therapy, infectious diseases and animal health. The Company's DepoVax™ platform is a patented formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system. Immunovaccine has advanced two DepoVax-based cancer vaccines into Phase I human clinical trials. The Company is also advancing a broad infectious disease pipeline including vaccines in such indications as malaria, respiratory syncytial virus (RSV) and anthrax. In addition to the Company's human health vaccine strategy, it continues to capture value from animal health vaccine applications. Immunovaccine has key partnerships in the animal health sector including an agreement with PfizerAnimal Health.
Since 2010, RetailInvestorConferences.com, created by BetterInvesting (NAIC) PR Newswire and MUNCmedia, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network and MUNCmedia's sophisticated retail investor targeting.
SOURCE Immunovaccine Inc.